Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06484777 | A Clinical Study of SHR-9539 in Patients With Multiple Myeloma | recruiting | Phase 1 | 138 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03398161 | Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04491370 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma |
| recruiting |
| Phase 1 / Phase 2 |
| 20 |
| New York Medical CollegeOTHER |
| 1 |
| Apr 15, 2026 |
| clinicaltrials |
| NCT05136807 | Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies | recruiting | — | 400 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | recruiting | Phase 1 / Phase 2 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | recruiting | Phase 2 | 150 | European Myeloma Network B.V.NETWORK | 4 | Apr 15, 2026 | clinicaltrials |
| NCT07356245 | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | recruiting | Phase 2 | 44 | Jonathan BrammerOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05996185 | Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma | recruiting | Phase 2 | 22 | Yale UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06544265 | SynKIR-310 for Relapsed/Refractory B-NHL | recruiting | Phase 1 | 36 | Verismo TherapeuticsINDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01890486 | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05481437 | A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma | recruiting | — | 8 | TakedaINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06145581 | Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma | recruiting | N/A | 25 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | recruiting | Phase 1 | 50 | FBD Biologics LimitedINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06923397 | Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial | recruiting | N/A | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07032714 | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma(MAGENTA) | recruiting | Phase 1 | 25 | Massachusetts General HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04234022 | Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma | recruiting | — | 70 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05183854 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | recruiting | Phase 2 | 61 | University of UtahOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05361694 | Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions(TRANSFORMM) | recruiting | — | 1,000 | University of MiamiOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05876923 | The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients | recruiting | N/A | 70 | Mayo ClinicOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04300998 | Study of CAR-T Therapy in Older Patients | recruiting | — | 154 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06048250 | Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07514052 | Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study | recruiting | — | 127 | Shanxi Bethune HospitalOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03587844 | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients | recruiting | Phase 2 | 58 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | recruiting | Phase 1 | 42 | Medical College of WisconsinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06208735 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | recruiting | Phase 1 | 24 | British Columbia Cancer AgencyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06252792 | Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma | recruiting | — | 50 | FengYan JinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06536413 | ATRA and Carfilzomib in Plasma Cell Myeloma Patients(ATRA) | recruiting | Phase 1 / Phase 2 | 42 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07069751 | A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma(HiFi-MM) | recruiting | N/A | 62 | Ciceri FabioOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia | recruiting | Phase 2 | 25 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04512534 | Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma(Sincerely20) | recruiting | Phase 2 | 51 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05257018 | R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | recruiting | Phase 2 | 83 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05862012 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | recruiting | Phase 1 | 200 | Ichnos Sciences SAINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT07030400 | Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | recruiting | — | 100 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | recruiting | Phase 1 / Phase 2 | 150 | Dizal PharmaceuticalsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07234487 | Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | recruiting | Phase 2 | 178 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06104592 | Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06536452 | Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects | recruiting | — | 50 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05898646 | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial | recruiting | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06270888 | Hypofractionation (Radiation) Trial for Multiple Myeloma | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06880913 | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07499271 | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation | recruiting | Phase 2 | 35 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 16, 2026source: clinicaltrials